<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941846</url>
  </required_header>
  <id_info>
    <org_study_id>2020111</org_study_id>
    <nct_id>NCT04941846</nct_id>
  </id_info>
  <brief_title>The Role of Deep Cerebral Vein Variation in Patients With Angiographic Negative Subarachnoid Hemorrhage</brief_title>
  <official_title>The Role of Deep Cerebral Vein Variation in Patients With Angiographic Negative Subarachnoid Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of Rosenthal basilar vein (BVR) variants (deep venous drainage variants) was&#xD;
      relatively increased in patients with AN-SAH compared with patients with aneurysms. However,&#xD;
      the inclusion criteria for AN-SAH patients in these studies were different. Some studies have&#xD;
      investigated both PAN-SAH and NPAN-SAH, while some studies have only investigated PAN-SAH&#xD;
      patients. However, we believe that NPAN-SAH may be the bleeding caused by non-BVR variation.&#xD;
      Although previous studies did not find any association between NPAN-SAH and BVR variants, the&#xD;
      results in their study were different, which may be due to the limited number of cases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>favorable or poor outcome</measure>
    <time_frame>1 year</time_frame>
    <description>poor outcome (mRS 2-6) or favorable outcome (mRS 0-1).</description>
  </primary_outcome>
  <enrollment type="Anticipated">296</enrollment>
  <condition>Subarachnoid Hemorrhage, Aneurysmal</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nimodipine and euvolemia</intervention_name>
    <description>administered nimodipine to prevent vasospasm, and euvolemia was maintained via intravenous hydration</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This project plans to include 296 patients who meet the admission and discharge criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with negative subarachnoid hemorrhage diagnosed by DSA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. In patients with aneurysms, external ventricular drainage (EVD) alone or decompression&#xD;
             craniotomy alone or conservative treatment was performed&#xD;
&#xD;
          2. Have a history of trauma or prior brain injury (stroke, cerebral hemorrhage, etc.,&#xD;
             with associated chronic changes on CT)&#xD;
&#xD;
          3. Patients with loss of imaging data and severe comorditions prior to onset of SAH&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Yuanjian Fang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>2ndAffiliated Hospital, School of Medicine, Zhejiang University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianmin Zhang, MD</last_name>
    <phone>+86 13805722695</phone>
    <email>zjm135@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sheng Chen, MD</last_name>
    <phone>+86 13645814323</phone>
    <email>saintchan@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>2ndAffiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianmin Zhang, MD</last_name>
      <phone>+86 13805722695</phone>
      <email>zjm135@zju.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Sheng Chen, MD</last_name>
      <phone>+86 13645814323</phone>
      <email>saintchan@zju.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Yuanjian Fang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nimodipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

